Xeris Biopharma Holdings
Open
$6.14
Prev. Close
$6.14
High
$6.16
Low
$6.12
Market Snapshot
$998.86M
1803.0
-0.38
$203.07M
435
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 435 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
emptyResult
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 435 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Recently from Cashu
Xeris Biopharma Holdings: Innovating Therapies for Improved Patient Outcomes and Engagement
Xeris Biopharma's Commitment to Innovative Therapies and Patient Outcomes Xeris Biopharma Holdings, Inc., a Chicago-based biopharmaceutical company, is dedicated to transforming patient outcomes throu…
Xeris Biopharma Holdings Projects $203 Million Revenue for 2024 Amid Product Expansion
Xeris Biopharma Sets Ambitious Revenue Goals for 2024 Amid Product Growth Xeris Biopharma Holdings, Inc., a Chicago-based biopharmaceutical company, announces a positive revenue forecast for 2024, est…
Xeris Biopharma Holdings Expands Workforce with 181,500 Inducement Equity Grants to New Employees
Xeris Biopharma Expands Workforce with Inducement Equity Grants Xeris Biopharma Holdings, Inc., a Chicago-based biopharmaceutical company, takes a significant step in enhancing its workforce by granti…
Xeris Biopharma Expands Workforce with 181,500 RSUs to Attract New Talent
Xeris Biopharma Expands Workforce with Strategic Inducement Grants Xeris Biopharma Holdings, Inc. announces a significant development as it grants restricted stock units (RSUs) totaling 181,500 shares…